[Influence of clinical status on the efficacy of stored platelet transfusion].
The efficiency of stored platelet transfusion was evaluated in terms of clinical status in 136 thrombocytopenic patients. In a paired prospective study in which fresh platelets were used as controls, clinical efficiency was assessed on the basis of the ability to increase platelet count (recovery) and the interval to the next transfusion (D). In 48 clinically stable patients, recovery of fresh and stored platelets was similar (47% and 41% respectively) and the interval to the next transfusion was D4 and D3. In contrast, 27 patients who had bacterial infections showed significantly different recoveries (24%/5%) and the interval to the next transfusion was D3/D1 for fresh and stored platelets respectively. Similarly, in 16 patients who were treated concurrently with Amphotericin B, 18 other patients with graft-versus-host disease, 5 with splenomegaly and 3 with veno-occlusive disease (VOD), fresh platelets performed better than stored platelets, showing recoveries of 27%/18%, 29%/15%, 15%/1%, 22%/3%. Furthermore, the need for retransfusion within 24 hours was significantly increased with stored platelets. In 19 patients with anti-HLA allo-immunization who were transfused with HLA-matched fresh and stored APC, efficiency was similar (38%/36% and D4/D3). This study indicates that the storage has a major detrimental effect on platelet recovery and survival in patients with certain clinical conditions.
Norol
F
F
Centre Départemental de Transfusion Sanguine du Val-de-Marne, Créteil, France.
Kuentz
M
M
Cordonnier
C
C
Beaujean
F
F
Haiouin
C
C
Vernant
J P
JP
Duedari
N
N
D000293:Adolescent; D000328:Adult; D000666:Amphotericin B / Q000494:pharmacology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects; D001792:Blood Platelets / Q000187:drug effects; D001793:Blood Preservation; D016465:Bone Marrow Purging / Q000009:adverse effects; D002470:Cell Survival; D005069:Evaluation Studies as Topic; D005260:Female; D006086:Graft vs Host Disease / Q000150:complications; D006504:Hepatic Veno-Occlusive Disease / Q000150:complications; D006648:Histocompatibility; D006801:Humans; D007239:Infections / Q000150:complications; D007938:Leukemia / Q000097:blood / Q000150:complications / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D010976:Platelet Count; D017713:Platelet Transfusion; D011446:Prospective Studies; D013163:Splenomegaly / Q000150:complications; D013921:Thrombocytopenia / Q000139:chemically induced / Q000150:complications / Q000628:therapy*; D016896:Treatment Outcome
D000666:Amphotericin B
Influence du statut clinique sur l'efficacité transfusionnelle des plaquettes conservées.